Will Beovu Be A Slow-Burning Blockbuster?
DME Data Boosts Novartis Eye Drug
Expanded indications will be key for Novartis's Beovu and a successful diabetic macular edema trial has provided a fillip, a week after the wet AMD-approved drug posted a 44% slump in sales.
You may also be interested in...
Cosentyx defied the odds again by growing strongly despite US formulary changes, COVID-19 and fierce competition, while the jump in Entresto sales helped soften the drug's failure in a closely watched myocardial infarction study.
Top-line Phase III data for faricimab in age-related macular degeneration leave Roche poised to file the bi-specific antibody for retinal diseases, but again there is no advantage with the novel dual-acting product over Eylea.
Initial data show non-inferiority to Eylea in diabetic macular edema with reduced frequency dosing but not superiority. Even so, market dynamics suggest it could still carve out blockbuster sales.